Evidence map›Paper›PMID 36523310›Full record

ArticleTranslational cancer research2022

Inhibitory role of puerarin on the A549 lung cancer cell line.

Jie Lang, Zhizhen Guo, Shushan Xing, Jian Sun, Bin Qiu, Yu Shu, Zhiqiang Wang, Guixiang Liu

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jie Lang *Department of Thoracic Surgery, Tangshan People's Hospital, Tangshan, China.
Zhizhen Guo *Department of Nephrology, Kailuan General Hospital, Tangshan, China.
Shushan Xing *Department of Oncology, Tangshan Central Hospital, Tangshan, China.
Jian SunDepartment of Thoracic Surgery, Tangshan People's Hospital, Tangshan, China.
Bin QiuDepartment of Thoracic Surgery, Tangshan People's Hospital, Tangshan, China.
Yu ShuDepartment of Thoracic Surgery, Tangshan People's Hospital, Tangshan, China.
Zhiqiang WangDepartment of Thoracic Surgery, Tangshan People's Hospital, Tangshan, China.
Guixiang LiuDepartment of Thoracic Surgery, Tangshan People's Hospital, Tangshan, China.
Tangshan People's Hospital · CNKailuan General Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Although more and more drugs had been proved to be effective in controlling tumor cells, lung cancer was still the leading cause of cancer-related deaths all over the world. This study aimed to investigate the effect and mechanism of puerarin on the invasion and metastasis of A549 lung cancer cell line. Methods: A medium containing puerarin was prepared according to the gradient concentration, and 10, 20, and 40 µmol/L were selected as the experimental group (low, medium, and high concentration groups, respectively) according to the cytotoxicity experiment. Meanwhile, 0 µmol/L was used as the control group. Results: Following administration, metastasis-related indexes were detected by the cell scratch test, cell migration test, gene difference detection, and western blotting. 24 hours after administration, the cell scratch and Transwell showed that the migration ability of A549 cells decreased with the increasing puerarin concentration. The polymerase chain reaction (PCR) and western blotting results demonstrated that the expression of the cell invasion and metastasis-related factor, matrix metallopeptidase 9 (MMP9), was negatively correlated with drug concentration. Further investigation demonstrated that the phosphorylation of extracellular signal-regulated kinase (ERK) was also inhibited. Conclusions: Puerarin can inhibit the expression of invasion and metastasis-related factors by inhibiting the phosphorylation of ERK.

Indexed as

extracellular signal-regulated kinase (ERK)invasionmetastasisPuerarin

Identifiers

PMID36523310
PMCPMC9745364
OpenAlexW4310811592

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.